{"prompt": "['Clinical Study Protocol', 'No. BAY 1021189 / 19334', '22 FEB 2018', 'Version no. 1.0', 'Page: 10 of 81', 'Table of contents', '1. Title page', '1', \"Signature of the sponsor's medically responsible person\", '2', 'Signature of principal investigator', '3', '2. Synopsis', '4', 'Table of tables', '12', 'Table of figures', '12', 'List of abbreviations', '13', '3. Introduction', '16', '3.1 Background', '16', '3.2', 'Previous experience in humans', '17', '3.2.1', 'Dose selection', '18', '3.3', 'Rationale of the study', '19', '4.', 'Study objectives', '20', '5.', 'Study design', '22', '6.', 'Study population', '23', '6.1', 'Inclusion criteria', '23', '6.2', 'Exclusion criteria', '24', '6.3', 'Withdrawal of patients from study', '26', '6.3.1', 'Withdrawal', '26', '6.3.2', 'Replacement', '28', '6.4', 'Patient identification', '28', '7.', 'Treatments', '28', '7.1', 'Treatments to be administered', '28', '7.2', 'Identity of study treatment', '29', '7.3', 'Treatment assignment', '30', '7.4', 'Dosage and administration', '30', '7.5', 'Blinding', '32', '7.6', 'Drug logistics and accountability', '33', '7.7', 'Treatment compliance', '34', '8.', 'Non-study therapy', '34', '8.1', 'Prior and concomitant therapy', '34', '8.2', 'Post-study therapy', '35', '9.', 'Procedures and variables', '36', '9.1', 'Tabular schedule of evaluations', '36', '9.2', 'Visit description', '37', '9.2.1', 'Visit 1 Screening Visit - Day -28-1', '38', '9.2.2', 'Visit 2 Baseline and Randomization - Day 1', '39', '9.2.3', 'Visit 3 - Day 14+3 (week 2)', '40', '9.2.4', 'Visit 4 - Day 28=3 (week 4)', '40']['Clinical Study Protocol', 'No. BAY 1021189 / 19334', '22 FEB 2018', 'Version no. 1.0', 'Page: 11 of 81', '9.2.5', 'Visit 5 - Day 42=3 (week 6)', '41', '9.2.6', 'Visit 6 - Day 56=3 (week 8)', '42', '9.2.7', 'Visit 7 - Day 84+3 (week 12)', '43', '9.2.8', 'Visit 8 - Day 126+3 (Week 18)', '43', '9.2.9', 'Visit 9 End of treatment - Day 168=7 (week 24)', '44', '9.2.10', 'Visit 10 Safety follow-up - Day 196+7', '45', '9.2.11', 'Premature discontinuation visit - at time of permanent discontinuation', '45', '9.2.12', 'Safety follow-up visit after premature discontinuation- 28 7 days after last dose 46', '9.3', 'Population characteristics', '46', '9.3.1', 'Demographic', '46', '9.3.2', 'Medical history', '47', '9.4', 'Efficacy', '47', '9.4.1', 'KCCQ', '48', '9.4.2', 'EQ-5D-5L', '50', '9.4.3', 'Patient Global Impression of Change (PGIC), and Severity (PGIS)', '50', '9.4.4', 'Fried frailty score', '50', '9.4.5', 'Assessment of NYHA class', '51', '9.4.6', 'NT-proBNP', '51', '9.4.7', 'Clinical outcome events', '52', '9.4.8', 'Six-minute walk test', '52', '9.5', 'Pharmacokinetics / pharmacodynamics', '52', '9.6', 'Safety', '53', '9.6.1', 'Adverse events', '53', '9.6.2', 'Pregnancies', '58', '9.6.3', 'Further safety', '58', '9.7', 'Other procedures and variables', '59', '9.7.1', 'Laboratory assessments', '59', '9.7.2', 'Physical examination', '60', '9.7.3', 'Echocardiography parameters', '60', '9.7.4', '12-lead ECG', '60', '9.7.5', 'Vital signs', '61', '9.7.6', 'Biomarkers', '61', '9.7.7', 'Optional pharmacogenetic research', '62', '9.7.8', 'Accelerometry', '62', '9.8', 'Appropriateness of procedures / measurements', '62', '10. Statistical methods and determination of sample size', '62', '10.1 General considerations', '62', '10.2', 'Analysis sets', '63', '10.3 Variables and planned statistical analyses', '63', '10.3.1 Efficacy variables', '63', '10.4', 'Determination of sample size', '65', '10.5 Planned interim analyses', '66', '10.6 PK and PK/QT analyses', '68', '11. Data handling and quality assurance', '68', '11.1 Data recording', '68', '11.2 Monitoring', '69', '11.3 Data processing', '70']\n\n###\n\n", "completion": "END"}